Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer

He,Zheng; Wu,Hui; Jiao,Yanli; Zheng,Jun

doi:10.3892/ol.2014.2751

Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer

Authors:
- Zheng He
- Hui Wu
- Yanli Jiao
- Jun Zheng
View Affiliations

Affiliations: Department of General Surgery, The First College of Clinical Medical Sciences, Three Gorges University, Yichang, Hubei 443002, P.R. China
Published online on: December 1, 2014 https://doi.org/10.3892/ol.2014.2751
Pages: 793-797

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD97 is a member of the epidermal growth factor‑seven transmembrane family. It affects tumor aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumors. However, little is known regarding the roles of CD97 and CD55 in pancreatic cancer. In this study, immunohistochemistry was used to analyze CD97 and CD55 protein expression in samples obtained from 37 pancreatic cancer patients. CD97 and CD55 were absent or only weakly expressed in the normal pancreatic tissues but strongly expressed in pancreatic cancer tissues (P<0.05), particularly in tissues with lymph node involvement, metastasis or vascular invasion (P<0.05). Notably, CD97 and CD55 were expressed consistently in pancreatic cancer tissues (r2=0.5422; P<0.05). In addition, CD97 and CD55 expression levels were found to significantly correlate with tumor aggressiveness (P<0.01). Multivariate analyses revealed that CD97 and CD55 expression levels were closely associated with prognosis (P<0.05). Taken together, these results indicated that CD97 and its ligand CD55 are upregulated in pancreatic cancers and are closely associated with lymph node involvement, metastasis and vascular invasion. Thus, analysis of both CD97 and CD55 expression may present potential prognostic value for pancreatic cancer.

View Figures

View References

1	Ma C, Jiang YX, Liu SZ, et al: Trend and prediction on the incidence of pancreatic cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi. 34:160–163. 2013.(In Chinese). PubMed/NCBI
2	Ji BT, Silverman DT, Dosemeci M, et al: Occupation and pancreatic cancer risk in Shanghai, China. Am J Ind Med. 35:76–81. 1999. View Article : Google Scholar : PubMed/NCBI
3	Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hamann J, Vogel B, van Schijndel GM and van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med. 184:1185–1189. 1996. View Article : Google Scholar : PubMed/NCBI
5	McKnight AJ and Gordon S: The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol. 63:271–280. 1998.PubMed/NCBI
6	Wobus M, Vogel B, Schmucking E, Hamann J and Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer. 112:815–822. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lin HH, Stacey M, Saxby C, et al: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem. 276:24160–24169. 2001. View Article : Google Scholar : PubMed/NCBI
8	Han SL, Xu C, Wu XL, et al: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis. 25:695–702. 2010. View Article : Google Scholar : PubMed/NCBI
9	Mustafa T, Eckert A, Klonisch T, et al: Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 14:108–119. 2005.PubMed/NCBI
10	Abbott RJ, Spendlove I, Roversi P, et al: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem. 282:22023–22032. 2007. View Article : Google Scholar : PubMed/NCBI
11	Hamann J, Stortelers C, Kiss-Toth E, et al: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol. 28:1701–1707. 1998. View Article : Google Scholar : PubMed/NCBI
12	Hamann J, Wishaupt JO, van Lier RA, et al: Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42:650–658. 1999. View Article : Google Scholar : PubMed/NCBI
13	Qian YM, Haino M, Kelly K and Song WC: Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology. 98:303–311. 1999. View Article : Google Scholar : PubMed/NCBI
14	Karpus ON, Veninga H, Hoek RM, et al: Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55. J Immunol. 190:3740–3748. 2013. View Article : Google Scholar : PubMed/NCBI
15	Edge SB, Byrd DR, Compton CC, et al: Exocrine and endocrine pancreas. AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 241–249. 2010
16	Tempero MA, Behrman S, Ben-Josef E, et al: Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 3:598–626. 2005.PubMed/NCBI
17	Barton MK: Thromboembolism is common and influences prognosis in patients with pancreatic cancer, study reports. CA Cancer J Clin. Jan 18–2012.(Epub ahead of print). View Article : Google Scholar
18	Yang GY, Wagner TD, Fuss M and Thomas CJ: Multimodality approaches for pancreatic cancer. CA Cancer J Clin. 55:352–367. 2005. View Article : Google Scholar : PubMed/NCBI
19	Mustafa T, Klonisch T, Hombach-Klonisch S, et al: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol. 24:285–294. 2004.PubMed/NCBI
20	Sutavani RV, Bradley RG, Ramage JM, et al: CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol. 191:5895–5903. 2013. View Article : Google Scholar : PubMed/NCBI
21	Durrant LG, Chapman MA, Buckley DJ, et al: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 52:638–642. 2003. View Article : Google Scholar : PubMed/NCBI
22	Liu Y, Chen L, Peng SY, Chen ZX and Hoang-Vu C: Role of CD97 (stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 6:913–918. 2005. View Article : Google Scholar : PubMed/NCBI
23	Loberg RD, Wojno KJ, Day LL and Pienta KJ: Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology. 66:1321–1326. 2005. View Article : Google Scholar : PubMed/NCBI
24	Wu J, Lei L, Wang S, Gu D and Zhang J: Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol. 2012:5876722012. View Article : Google Scholar : PubMed/NCBI